Skip to main content
TipRanks
Go Ultimate75% OFF

Rapid Micro Biosystems (RPID) AI Stock Analysis

111 Followers
RPID

Rapid Micro Biosystems

(NASDAQ:RPID)

Select Model
Rating:50Neutral
Price Target:$0.74â–²(0.54% Upside)
Action:reiterated
Date:11/17/26

The score is held down primarily by weak financial performance—large ongoing losses, sustained cash burn, and rising leverage—despite improving gross margin and revenue growth. Technicals remain weak with the stock below key longer-term moving averages. Offsetting these risks are constructive earnings-call progress (reaffirmed/raised operational targets and improving margin outlook) and a highly supportive corporate event: a signed all-cash acquisition agreement at $0.75 per share.

Positive Factors
Recurring Revenue ExpansionGrowth in recurring revenue and the validated installed base supports a more durable business model than one-time instrument sales alone. As customers use the platform routinely, consumables and service revenue can compound, improving revenue visibility and strengthening customer retention over the next several quarters.
Negative Factors
Persistent Operating LossesLarge recurring net and EBITDA losses show that revenue growth has not yet produced sustainable operating leverage. Until expenses scale more efficiently and product economics improve, the company remains exposed to continued losses and may have less flexibility to invest in growth or absorb execution setbacks.

Rapid Micro Biosystems (RPID) vs. SPDR S&P 500 ETF (SPY)

-100%-80%-60%-40%-20%0%20%RPID-81.87%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$33.64M
Dividend Yield
―
Average Volume (3M)
540.87K
Price to Earnings (P/E)
-0.7
Beta (1Y)
1.39
Revenue Growth
20.78%
EPS Growth
-9.39%
Country
US
Employees
171
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Rapid Micro Biosystems Business Overview & Revenue Model

Company Description

Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America,...

How the Company Makes Money

Rapid Micro Biosystems makes money primarily by selling its Growth Direct systems and then generating recurring revenue from the installed base through consumables and services. Key revenue streams include: (1) Instrument/system sales: one-time reven...

Rapid Micro Biosystems Earnings Call Summary

Earnings Call Date:Aug 07, 2026(Q2-2026)|% Change Since:-64.62%|Next Earnings Date:Feb 26, 2027
Earnings Call SentimentPositive

The call conveyed clear operational momentum: double-digit revenue growth (11% YoY), record consumable performance (>20% growth), a company milestone (200th system), a sizable increase in service margins (to 49%), and a pathway to improving gross margins through H2 2026 and longer-term targets (50% by end of 2028). At the same time, the company remains unprofitable with a Q2 net loss of $12.9M and adjusted EBITDA loss of $10.3M, product margins are still slightly negative, and liquidity depends on achieving debt milestone funding and potential warrant exercises. Overall, management emphasized improving fundamentals and execution while acknowledging remaining execution and financing risks.

Positive Updates

Revenue Growth and Reaffirmed Full-Year Guidance
Total Q2 revenue of $8.1M, up 11% year-over-year (from $7.3M). Company reaffirmed full-year 2026 revenue guidance of $37M to $41M and guidance for 30 to 38 system placements.

Negative Updates

Continued Net Losses and Adjusted EBITDA Loss
Q2 net loss of $12.9M (vs. $11.9M prior year) and net loss per share of $0.27 (unchanged). Adjusted EBITDA loss was $10.3M in Q2 (worse than $10.1M in Q2 last year), indicating continued significant operating losses despite margin improvements.

Company Guidance

Rapid Micro reaffirmed full‑year 2026 guidance of $37–$41 million in revenue and 30–38 system placements, raised validation guidance to at least 27 completions (with ≥10 in Q3), and expects full‑year gross margin of ~20% (product margin mid‑to‑high single digits; service margin 45–50%). For Q3 they forecast at least $9.5 million of revenue (including ≥7 system placements) and Q3 gross margin ≥20%, with Q4 gross margin targeted in the mid‑to‑high‑20% range (product margin high‑single to low‑double digits; service margin ~50%). They also guided FY OpEx of $51–$53 million, $8 million of non‑cash expense (~$3M D&A, $5M stock comp), $1M CapEx, $1M interest income and $2M interest expense, reported ~ $20M cash at quarter‑end, expect to access a $10M debt tranche later this year (another $10M possible mid‑2027), and are targeting >20% average annual revenue growth and a 50%+ gross margin exit by 2028 with positive cash flow by end‑2028.

Rapid Micro Biosystems Financial Statement Overview

Summary

Despite strong multi-year and TTM revenue growth and improving gross margin (now positive), results remain dominated by deep operating/net losses, consistently negative operating and free cash flow, and rising leverage as equity shrinks—keeping liquidity and financing risk elevated.

Income Statement

32Negative

Balance Sheet

44Neutral

Cash Flow

28Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue35.18M33.59M28.05M22.52M17.13M23.23M
Gross Profit3.53M7.61M-109.00K-5.49M-8.54M-7.74M
EBITDA-45.64M-42.74M-43.51M-49.33M-58.55M-69.25M
Net Income-51.20M-47.12M-46.89M-52.47M-60.81M-73.52M
Balance Sheet
Total Assets58.45M74.85M98.17M143.45M190.65M241.17M
Cash, Cash Equivalents and Short-Term Investments19.77M38.30M50.73M92.05M108.65M193.50M
Total Debt23.48M23.87M6.17M7.35M7.97M0
Total Liabilities40.70M41.65M22.82M25.46M26.48M20.19M
Stockholders Equity17.75M33.21M75.35M117.99M164.17M220.98M
Cash Flow
Free Cash Flow-40.39M-31.91M-45.52M-46.93M-65.29M-58.18M
Operating Cash Flow-40.06M-31.06M-44.15M-45.08M-58.55M-54.96M
Investing Cash Flow7.12M14.33M36.66M42.15M-93.47M-13.29M
Financing Cash Flow29.29M19.77M203.00K149.00K693.00K216.75M

Rapid Micro Biosystems Technical Analysis

Technical Analysis SentimentNeutral
Last Price0.74

Price Trends

50DMA0.90Negative
100DMA1.35Negative
200DMA2.02Negative

Market Momentum

MACD-0.06Negative
RSI44.93Neutral
STOCH62.20Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPID, the sentiment is Neutral. The current price of 0.74 is above the 20-day moving average (MA) of 0.73, below the 50-day MA of 0.90, and below the 200-day MA of 2.02, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 44.93 is Neutral, neither overbought nor oversold. The STOCH value of 62.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RPID.

Rapid Micro Biosystems Risk Analysis

Rapid Micro Biosystems disclosed 69 risk factors in its most recent earnings report. Rapid Micro Biosystems reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our failure or perceived failure to achieve or maintain corporate sustainability practices that meet evolving stakeholder expectations could adversely affect us.Q4, 2025
2.Our existing and any future indebtedness could adversely affect our ability to operate our business.Q4, 2025
3.We may not realize the intended benefits of our strategic partnerships and other collaborations, and such relationships may introduce additional risks to our business.Q4, 2024

Rapid Micro Biosystems Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RPID against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SGHTSGHT62Neutral$583.02M-20.15-51.66%―16.23%41.47%
LNSRLNSR59Neutral$60.36M4.17549.37%―1.59%―
LUNGLUNG59Neutral$119.11M-2.71-98.23%―-3.15%28.45%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
RPIDRPID50Neutral$36.96M-0.67-254.31%―20.78%-9.39%
LUCDLUCD48Neutral$82.58M-0.95-610.65%―23.60%54.50%
HYPRHYPR47Neutral$59.64M-1.87-82.89%―79.96%42.64%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%RPIDLUNGLNSRHYPRSGHTLUCDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RPID and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RPIDRapid Micro Biosystems, Inc. Class A0.74-3.62-83.12%
LUNGPulmonx Corporation2.731.3598.19%
LNSRLensar Inc4.91-5.13-51.10%
HYPRHyperfine Inc.0.56-0.51-47.57%
SGHTSight Sciences, Inc.10.493.5651.37%
LUCDLucid Diagnostics Inc.0.40-0.62-60.88%

Rapid Micro Biosystems Corporate Events

M&A Transactions

Rapid Micro Biosystems Agrees to Merck Acquisition

Positive
Nov 16, 2026

On November 16, 2026, Rapid Micro Biosystems entered a definitive agreement under which Merck KGaA, Darmstadt, Germany, agreed to acquire all outstanding Rapid shares for $0.75 each in cash. The agreement provided for a tender offer followed by a mer...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026